Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
World game at war: why some European nations have threatened a World Cup boycott 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
CARMIEL, Israel, April 26, 2018 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report first quarter 2018 financial results and provide a corporate update on Wednesday, May 9, 2018 at 8:30 am ET.
To participate in the conference call, please dial the following numbers prior to the start of the call: United States: +1-844-358-6760; International: +1-478-219-0004. Conference ID number 8190507.
The conference call will also be broadcast live and available for replay for two weeks on the Company’s website, www.protalix.com, in the Events Calendar of the Investors section. Please access the Company’s website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has entered into an ex-United States partnership with Chiesi Farmaceutici S.p.A. for the development and commercialization of pegunigalsidase alfa. Protalix maintains full rights to pegunigalsidase alfa in the United States.
Investor Contact
Marcy Nanus
Solebury Trout
646-378-2927
[email protected]
